Plain-English plan summary
According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, Allogene Therapeutics, Inc. 401(K) Plan is a benefit plan reported by Allogene Therapeutics, Inc. under EIN 82-3562771 and plan number 001. The latest loaded filing year is 2023. The filing reports 453 participants and $36,149,510 in end-of-year plan assets, where available in the loaded dataset.
Reported financial statement (2023 · Schedule H)
Net assets
- Total assets (EOY)
- $36,149,510
- Total liabilities (EOY)
- $0
- Net assets (EOY)
- $36,149,510
- Net assets (BOY)
- $25,695,101
Income & contributions
- Employer contributions
- $2,459,350
- Participant contributions
- $5,625,338
- Total contributions
- $9,114,525
- Total income / additions
- $15,178,572
Expenses & distributions
- Benefits paid
- $4,715,847
- Administrative expenses
- -$20,471
- Total expenses
- $4,724,163
- Net increase / (decrease)
- $10,454,409